Post-traumatic stress disorder

American Humane Applauds President Biden for Signing PAWS Act, Looks Ahead to Implementation

Retrieved on: 
Thursday, August 26, 2021
Heel, Non-governmental organization, Suicidal ideation, Man, Veterans Health Administration, United States Department of Veterans Affairs, Post-traumatic stress disorder, Animal, TBI, PAWS, Multimedia, Checklist, Safety, Veterans' affairs, Depression, CEO, Organization, Dog, PTS, Puppy, Woman, Department, PTSD, Pharmaceutical industry, Management, Real estate

WASHINGTON, Aug. 26, 2021 /PRNewswire/ -- American Humane, the country's first national humane organization, applauds President Biden for signing the Puppies Assisting Wounded Servicemembers (PAWS) Act, which when implemented will empower the Department of Defense to fund service dogs for veterans struggling with post-traumatic stress disorder.

Key Points: 
  • WASHINGTON, Aug. 26, 2021 /PRNewswire/ -- American Humane, the country's first national humane organization, applauds President Biden for signing the Puppies Assisting Wounded Servicemembers (PAWS) Act, which when implemented will empower the Department of Defense to fund service dogs for veterans struggling with post-traumatic stress disorder.
  • "American Humane is heartened and encouraged by the bipartisan support for the PAWS Act, which will improve the lives of veterans across the country," said Robin R. Ganzert, Ph.D., president and CEO of American Humane.
  • The momentum behind the PAWS Act comes on the heels of a Veterans Health Administration study, the results of which were released earlier this year.
  • "American Humane is honored to provide lifechanging and life-saving service dogs to veterans in need through our Pups4Patriotsprogram," said Dr. Ganzert.

Virpax Announces MMS019 Manufacturing and Supply Agreement

Retrieved on: 
Thursday, August 26, 2021
Science, Other Science, Biotechnology, Pharmaceutical, Surgery, Health, Infectious Diseases, Other Health, Industry, Company, Nanoparticle, Bupivacaine, Securities Exchange Act of 1934, CNS, Pain, Drug Quality and Security Act, Cancer, Severe acute respiratory syndrome coronavirus 2, U.S. Securities and Exchange Commission, Nature, Nanotechnology, Research, Private Securities Litigation Reform Act, Cosmetics, Social responsibility, Post-traumatic stress disorder, Electronics, Securities Act of 1933, Osteoarthritis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NASDAQ, Pain management, MET, Morphine, Food, Chronic pain, CEO, Culture, FDA, Brain, COVID-19, PTSD, Spray drying, Security (finance), Pharmaceutical industry, Fine chemical, Vaccine, Risk management, MMS019, Seqens, Virpax Pharmaceuticals, MMS019, SEQENS, VIRPAX PHARMACEUTICALS

The agreement with Seqens provides for both the supply material for Virpaxs clinical studies as well as the long-term commercial supply of MMS019.

Key Points: 
  • The agreement with Seqens provides for both the supply material for Virpaxs clinical studies as well as the long-term commercial supply of MMS019.
  • Seqens will conduct process development and validation of additional large scale commercial quantities of MMS019 at its facilities in Devens and Newburyport, Massachusetts.
  • Establishing a collaboration with a strong partner capable of supplying clinical and commercial scale quantities of MMS019 is another important advancement in our MMS019 product development strategy.
  • Seqens has a demonstrated expertise in developing and manufacturing highly-complex molecules for large scale production, said Anthony Mack, Chairman and CEO of Virpax.

BetterLife Initiates Preclinical Study of AP-003 (rhIFNa2b) against Delta Variant of SARS-CoV-2

Retrieved on: 
Wednesday, August 25, 2021
Lists of diseases, Company, CAGR, Migraine, Neuro, Associate, Degenerative disease, CSE, Therapy, Severe acute respiratory syndrome coronavirus 2, Level 3, GLOBE, Anxiety, Method, Hospital, Infection, Disability, Pandemic, Coronavirus, Research, Containment, Microbiology, Western University, Doctor of Philosophy, Death, Insomnia, Post-traumatic stress disorder, Impakt Festival, Tablet, Plasma protein binding, UWO, IND, Risk, WHO, Depression, Vaccine, CEO, HIV, B.1.1.7, COVID-19, Department, Patent, Pharmaceutical industry

The studies are being conducted at Dr. Stephen Barrs Laboratory at the state-of-the-art ImPaKT Facility at Western University (UWO).

Key Points: 
  • The studies are being conducted at Dr. Stephen Barrs Laboratory at the state-of-the-art ImPaKT Facility at Western University (UWO).
  • The Company expects to release the results on the of rhIFN2b /AP-003 activity against Delta variant in the next two weeks.
  • The broad mechanism of action of interferon is such that our scientists hypothesized it could be equally effective against different variants.
  • TD-010, which is in Preclinical and IND-enabling studies, is based on Honokiol, the active anxiolytic ingredient of magnolia bark.

McQuade Center for Strategic Research and Development Enters Collaboration with Aché to Develop Potential Treatment for General Anxiety Disorder and Post-Traumatic Stress Disorder

Retrieved on: 
Tuesday, August 24, 2021
Biotechnology, Mental Health, Health, Pharmaceutical, Clinical Trials, Nephrology, Commercialization, LLC, CNS, Twitter, Innovation Unit, Maintenance, Cardiology, Tuberculosis, Research, Drug discovery, Cosmetics, National university, Doctor of Philosophy, Health, OAPI, Post-traumatic stress disorder, Heart, Mental health, Development, GAD, Creativity, LinkedIn, Patient, Plasma protein binding, PTSD, Pharmaceutical industry, Aché Laboratorios Farmaceuticos S.A., McQuade Center for Strategic Research and Development (MSRD), ACHé LABORATORIOS FARMACEUTICOS S.A., MCQUADE CENTER FOR STRATEGIC RESEARCH AND DEVELOPMENT (MSRD)

Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.

Key Points: 
  • Therefore, medications with new mechanisms of action are needed with the potential to achieve better therapeutic responses.
  • We are absolutely thrilled with this collaboration with MSRD, a member of Otsuka, said Vnia Alcantara Machado, president, Ach.
  • We believe MSRDs expertise in early-stage programs and Otsukas global leadership position in CNS will be crucial in the development of Achs ACH000029 for GAD and PTSD.
  • Ach has a dedicated Innovation Unit focused on the research and development of new medicines, generics, and similar drugs.

Wounded Warrior Project to Call and Support 40,000 Afghanistan Veterans

Retrieved on: 
Thursday, August 19, 2021
Wounded Warrior Project, Afghanistan War Memorial, Kyiv, Traumatic brain injury, WWP, Suicide, Post-traumatic stress disorder, Time, Veteran, TBI, Mental health, Afghan, Multimedia, Asian American university resource center, News, Caregiver, Organization, PTSD, Medicine

JACKSONVILLE, Fla., Aug. 19, 2021 /PRNewswire/ --Wounded Warrior Project (WWP) is mounting a campaign to call and offer support to approximately 40,000 veterans of the Afghanistan War amid recent developments.

Key Points: 
  • JACKSONVILLE, Fla., Aug. 19, 2021 /PRNewswire/ --Wounded Warrior Project (WWP) is mounting a campaign to call and offer support to approximately 40,000 veterans of the Afghanistan War amid recent developments.
  • "We understand and acknowledge what's happening in Afghanistan may bring back some difficult memories and trigger strong feelings," said Jennifer Silva, WWP chief program officer.
  • "Wounded Warrior Project is here for the warriors on the front line and for you who have given so much for the Afghan people and each other."
  • Since 2003, Wounded Warrior Project (WWP) has been meeting the growing needs of warriors, their families, and caregivers helping them achieve their highest ambition.

Seven In 10 Americans Planning To Travel With Their Pet This Year Say Their Pet Deserves A Getaway

Retrieved on: 
Wednesday, August 18, 2021
Socialization, Texas Department of Public Safety, Human, PETS, Family, Anxiety, Thought, CDC, Texas A&M University, Research, Nausea, Travel, Texas Department of Criminal Justice, Ageing, Age-related mobility disability, Post-traumatic stress disorder, Cat, Motel, Motel 6, Partnership, CEO, Dog, Dallas–Fort Worth metroplex, Water, PTSD, Pet, Trapping, Hotel

The pollfound that nearly seven in 10 (68%) say their pet deserves a getaway this year, but only 8% of respondents prepare for a trip with their four-legged friend by researching pet-friendly travel websites.

Key Points: 
  • The pollfound that nearly seven in 10 (68%) say their pet deserves a getaway this year, but only 8% of respondents prepare for a trip with their four-legged friend by researching pet-friendly travel websites.
  • In fact, two in five (41%) individuals planning to travel with their pet in the next year agree that their pet can't travel without their favorite toy.
  • More than one-third of those planning to travel with their pet within the next year (39%) say the next trip they plan to take is a road trip.
  • Nearly two in three (65%) individuals planning to travel with their pet in the next year believe pet-friendly hotels should not charge extra for a pet.

Mental and Nervous Long-Term Disability Claims for Healthcare Professionals Jumped Significantly in 2020

Retrieved on: 
Tuesday, August 17, 2021
Nervous system, Substance abuse, Drug, American Journal, Mental, Parkinson, Incidence, SALT, Parkinson's disease, Policy, Physician, Yale School of Public Health, Health, Suicide, Post-traumatic stress disorder, Mental health, Multimedia, The Washington Post, Depression, Public health, Kaiser Family Foundation, MNDA, COVID-19, The American Journal of Medicine, Multiple sclerosis, Health insurance, Pharmaceutical industry, Medicine

Mental and Nervous disability claims filed in 2020 (11.5% of total claims) reflected an 85.8% increase over those filed in 2019 (6.7% of total claims).

Key Points: 
  • Mental and Nervous disability claims filed in 2020 (11.5% of total claims) reflected an 85.8% increase over those filed in 2019 (6.7% of total claims).
  • A 2020 North Carolina State University study found that on average, healthcare professionals reported enough symptoms of depression to be diagnosed with clinical depression.
  • According to the tally of long-term disability claims submitted in 2020 by healthcare professionals insured by MGIS, the top five reasons for filing the claims were:
    (tie) Nervous System (Parkinson's disease, multiple sclerosis)
    "The increased incidence of mental health disabilities last year highlights the importance of comprehensive disability insurance for healthcare professionals," Brunken explained.
  • MGIS is a leading national insurance program manager that builds and manages specialized insurance programs for healthcare professionals.

Virpax® Pharmaceuticals Receives FDA Response and Guidance on MMS019

Retrieved on: 
Tuesday, August 17, 2021
Research, Surgery, Infectious Diseases, FDA, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Plasma protein binding, Industry, Company, Nanoparticle, Bupivacaine, Human, Sponsor, Securities Exchange Act of 1934, CNS, Observation, Program, Pain, Virus, Drug Quality and Security Act, Severe acute respiratory syndrome coronavirus 2, Cancer, U.S. Securities and Exchange Commission, Nature, Communication, Nanotechnology, Research, Private Securities Litigation Reform Act, Food, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Animal, Post-traumatic stress disorder, NDA, Securities Act of 1933, Clinical trial, Osteoarthritis, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., NASDAQ, Pain management, OTC, Morphine, Chronic pain, MET, Survivor, CEO, FDA, Brain, COVID-19, PTSD, Spray drying, Security (finance), Pharmaceutical industry, Vaccine, Risk management, MMS019, Virpax Pharmaceuticals, MMS019, VIRPAX PHARMACEUTICALS

Virpax believes the results of the pre-IND response support further research on MMS019 as an intranasal protective that may limit transmission of the viruses to others.

Key Points: 
  • Virpax believes the results of the pre-IND response support further research on MMS019 as an intranasal protective that may limit transmission of the viruses to others.
  • Virpax expects to move forward and pursue a New Drug Application (NDA) for MMS019 as a once daily intranasal treatment.
  • The FDA has indicated that Virpax may pursue an NDA drug approval with the Office of Non-Prescription Drugs.
  • We believe that the initial pathway to move forward with the development of MMS019 has been clarified, said Anthony P. Mack, Chairman and CEO of Virpax.

Clinical Trial Application Submitted to Health Canada for Experiential, Psychedelic-Assisted Psychotherapy Training

Retrieved on: 
Tuesday, August 17, 2021
AB, Industry, State bureau of investigation, ATMA, Blood pressure, CANADA, Heart rate, Mental, Tran, Mental health, Travel, Vital signs, Post-traumatic stress disorder, CTA, Learning, Philosophy, Tic disorder, Safety, Partnership, Patient, Depression, Beauty, Health Canada, Trial, Publication, Psilocybin, Thermoregulation, Pharmaceutical industry, Medicine

CLINICAL TRIAL APPLICATION SUBMITTED TO HEALTH CANADA FOR EXPERIENTIAL, PSYCHEDELIC-ASSISTED PSYCHOTHERAPY TRAINING

Key Points: 
  • CLINICAL TRIAL APPLICATION SUBMITTED TO HEALTH CANADA FOR EXPERIENTIAL, PSYCHEDELIC-ASSISTED PSYCHOTHERAPY TRAINING
    Therapists are integral to psychedelic-assisted psychotherapy, and the need to provide accessible and robust training experiences for therapists is a crucial objective as the need for psychedelic-assisted treatment continues to grow.
  • ATMA is pleased to announce the completion of its first clinical trial application (CTA).
  • If ATMA's application to Health Canada is successful, therapists will now be able to engage in experiential learning and training opportunities on Canadian soil.
  • The mental health professionals at Wayfound bring years of experience working with clients across the lifespan and suffering from various mental health conditions.

Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2021 Financial Results

Retrieved on: 
Monday, August 16, 2021
U.S. Securities and Exchange Commission, MDD, Judgement, Clinical trial, Lists of diseases, Epilepsy, ET, Foundation Medicine, PTSD, Growth, CNS, Medicare Part D, SUNCT, Private Securities Litigation Reform Act, Woman, Safety, Review, ASSR, Central nervous system, Post-traumatic stress disorder, Company, Food, LinkedIn, Movement disorders, MAD, IND, FDA, Annual report, PMD, Depression, Investigational New Drug, ASO, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Adult, Goal, Essential tremor, Trigeminal neuralgia, COVID-19, Conjunctiva, Pharmacokinetics, Investment, Exercise, Ageing, Dees, NASDAQ, Research, Autonomic, Central nervous system disease, SUNA, Brain, Twitter, EEG, GLOBE, Security (finance), Patient, SAD, PK, Animal, Cryptocurrency, Pharmaceutical industry, Lithium

The second quarter marked another inflection point for Praxis as we make progress toward being a diversified, late-stage, CNS focused company, said Marcio Souza, president and chief executive officer of Praxis.

Key Points: 
  • The second quarter marked another inflection point for Praxis as we make progress toward being a diversified, late-stage, CNS focused company, said Marcio Souza, president and chief executive officer of Praxis.
  • Praxis expects topline results from the ongoing PRAX-114 Phase 2/3 Aria Study for monotherapy treatment of MDD in the first half of 2022.
  • Praxis plans to initiate a PRAX-114 Phase 2 placebo-controlled study for treatment of post-traumatic stress disorder (PTSD) in the second half of 2021.
  • Second Quarter 2021 Financial Results:
    As of June 30, 2021, Praxis had $339.2 million in cash, cash equivalents and marketable securities, compared to $296.6 million in cash and cash equivalents as of December 31, 2020.